I think it may have been more about the NY Times article. It got an awful lot of attention. The issue with Gloucester is look at the price Celgene paid and look at Allos market cap :)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.